1. 1) Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare, “A report on investigation of side effects of sorivudine: Deaths caused by interactions between sorivudine and 5-FU prodrugs,” 1994, pp. 1-27.
2. 2) Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., Sugiyama Y., Pharmacol. Rev., 50, 387-412 (1998).
3. 3) Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., Ishizaki T., Green C. E., Tyson C. A., Sugiyama Y., Pharmacol. Ther., 73, 147-171 (1997).
4. 4) Rostami-Hodjegan A., Clin. Pharmacol. Ther., 92, 50-61 (2012).
5. 5) Jones H. M., Chen Y., Gibson C., Heimbach T., Parrott N., Peters S. A., Snoeys J., Upreti V. V., Zheng M., Hall S. D., Clin. Pharmacol. Ther., 97, 247-262 (2015).